Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05946551 · ClinicalTrials.gov registry record · Phase 3
Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
A Phase 3 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT05946551: Clinical Trial Phase 3 study, sponsored by Emory University.
NCT05946551 is a Phase 3 study that was terminated before completion, run by Emory University. The registered enrollment target is 5 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05946551, a Phase 3 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the feasibility and acceptability of methods and procedures to be employed in a larger scale decentralized platform adaptive randomized clinical trial in patients with a history of a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Polymerase Chain Reaction (PCR) positive test and/or medical records from a healthcare provider that coincides with the diagnosis of long-COVID.
Primary Outcome
The number of participants that had any confusion over how to take the study drug, including which pill to take, when to take it, or how many to take will be recorded as part of the end-of-study survey.
Interventions
- DRUG Famotidine
- DRUG Cetirizine
- DRUG Cetirizine Placebo
- DRUG Famotidine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-03-08 |
| Est. Completion | 2024-06-24 |
| Phase | Phase 3 |
Why NCT05946551 stopped before completion
NCT05946551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which Famotidine is the first listed.
NCT05946551 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05946551 about?
NCT05946551 is a clinical study titled "Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial". The primary objective of this study is to assess the feasibility and acceptability of methods and procedures to be employed in a larger scale decentralized platform adaptive randomized clinical trial in patients with a history of a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Polymer...
What is the current status of trial NCT05946551?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2024-03-08. Estimated completion is 2024-06-24.
What interventions are being tested in trial NCT05946551?
The interventions under investigation include: Famotidine (DRUG), Cetirizine (DRUG), Cetirizine Placebo (DRUG), Famotidine Placebo (DRUG).
Who is sponsoring clinical trial NCT05946551?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05946551's enrollment target sits among peer trials
5 1997th of 2000 higher than 3 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI